In its Tuesday night announcement, Adventrx suggested the Exelbine rejection may force the company to put the drug on the shelf so it can focus on two other drugs in its pipeline. Those are ANX-514, another reformulation project, this one of the generic cancer drug taxotere; and ANX-188, an old (and previously failed) drug for sickle cell anemia.

To move ANX-514 and ANX-188 forward, Adventrx must design and executive clinical trials, a skill the company lacks. If a "drug company" can't run clinical trials, it can't develop drugs. And if a "drug company" can't develop drugs, it doesn't deserve to be called a "drug company."

Adventrx is not a drug company. It's a cash-burning, shareholder value-losing exercise in futility.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

4 Biotech Stocks Under $10 Moving Higher

For Biotech, 'Fail' is Making a Big Comeback

ADVENTRX Stock Gaps Down On Today's Open (ANX)

ADVENTRX Stock Gaps Down On Today's Open (ANX)

5 Stocks Under $10 Setting Up to Trade Higher

5 Stocks Under $10 Setting Up to Trade Higher

5 Stocks Setting Up to Break Out